Area of research
Infectious Diseases · Emergency Medicine
Research interest
Research interests include HIV/AIDS Research and Interventions, HIV-related health complications and treatments, HIV, Drug Use, Sexual Risk, and Healthcare Systems and Practices.
Shared and disorder-specific prenatal and perinatal risk factors for neurodevelopmental disorders: a nationwide cohort study.
Identification of major congenital malformations based on healthcare databases in France: A proof-of-concept study using the epi-meres nationwide mother-child register.
Identification of Major Congenital Malformations based on Healthcare Databases in France: a Proof-of-Concept Study using the EPI-MERES Nationwide Mother-Child Register
Trends in Prenatal Exposure to Antiseizure Medications Over the Past Decade: A Nationwide Study.
Shared and Disorder-Specific Prenatal and Perinatal Risk Factors for Neurodevelopmental Disorders: A nationwide cohort study.
Contraceptive use in France in 2012 and 2022: a descriptive analysis of two repeated nationwide cross-sectional studies.
Supplementary data from Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case–Control Study Based on the French National Health Data System (SNDS)
Data from Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case–Control Study Based on the French National Health Data System (SNDS)
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis.
Response to "On the risk of using raw regional data on new HIV infections in France" by Tassi et al.
Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children.
Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
Association Between Doses of Levonorgestrel Intrauterine Systems and Subsequent Use of Psychotropic Drugs in France.
Spatio‐temporal changes in pre‐exposure prophylaxis uptake among MSM in mainland France between 2016 and 2021: a Bayesian small area approach with MSM population estimation
Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
Spatio-temporal changes in pre-exposure prophylaxis uptake among MSM in mainland France between 2016 and 2021: a Bayesian small area approach with MSM population estimation.
Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study.
Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010-19 period.
Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010-2019.
Trends in anti-infective use during pregnancy in France between 2010 and 2019: a nationwide population-based study.
Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig <i>et al</i>. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France.
Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population-based study.
Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Roll-out and effectiveness of HIV pre-exposure prophylaxis in France: An overview.
Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines.
Impact of coronavirus disease 2019 on contraception use in France.
Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older.
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.